We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Long Term Study With B2036-PEG

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00143416
Recruitment Status : Completed
First Posted : September 2, 2005
Last Update Posted : July 29, 2008
Information provided by:

September 1, 2005
September 2, 2005
July 29, 2008
April 2004
Not Provided
To evaluate the safety and efficacy of long-term B2036-PEG therapy in patients with acromegaly
Same as current
Complete list of historical versions of study NCT00143416 on ClinicalTrials.gov Archive Site
PK/PD evaluation
Same as current
Not Provided
Not Provided
Long Term Study With B2036-PEG
Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG -
Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.
Not Provided
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Drug: Pegvisomant
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
July 2007
Not Provided

Inclusion Criteria:

  • Patients with acromegaly who have received at least one dose of B2036-PEG in the preceding study (A6291009).

Exclusion Criteria:

  • Switching to other therapeutic methods for acromegaly
Sexes Eligible for Study: All
20 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP